Literature DB >> 6441696

Hyperosmolarity response of ocular standing potential as a clinical test for retinal pigment epithelium activity diabetic retinopathy.

K Kawasaki, D Yonemura, S Madachi-Yamamoto.   

Abstract

The hyperosmolarity response, a drug-induced response from the retinal pigment epithelium, was recorded in diabetic retinopathy. The hyperosmolarity response was occasionally abnormal at the pre-retinopathic stage and at the first stage of retinopathy by Scott classification. The response was frequently abnormal at the second and third stages of retinopathy. The hyperosmolarity response is useful for early diagnosis of pigment epitheliopathy in diabetes.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6441696     DOI: 10.1007/bf00679800

Source DB:  PubMed          Journal:  Doc Ophthalmol        ISSN: 0012-4486            Impact factor:   2.379


  13 in total

1.  New approaches to ophthalmic electrodiagnosis by retinal oscillatory potential, drug-induced responses from retinal pigment epithelium and cone potential.

Authors:  D Yonemura; K Kawasaki
Journal:  Doc Ophthalmol       Date:  1979-12-14       Impact factor: 2.379

2.  [On the electron microscopic investigations of the Bruch's menbrane and choriocapillaries in human diabetes mellitus (author's transl)].

Authors:  K Kojima; T Harada; S Miyake
Journal:  Nippon Ganka Gakkai Zasshi       Date:  1976-12-10

3.  Retinal repair after experimental xenon arc photocoagulation. I. A comparison between rhesus monkey and rabbit.

Authors:  I H Wallow; M O Tso; B S Fine
Journal:  Am J Ophthalmol       Date:  1973-01       Impact factor: 5.258

4.  [Histological studies of repairing processes after xenon photocoagulation in the monkey retina. 2. Electron microscopic studies on cellular responces in the late repairing stage (author's transl)].

Authors:  Y Ishikawa
Journal:  Nippon Ganka Gakkai Zasshi       Date:  1975-11-10

5.  [Diamox response of ocular standing potential as a clinical test for retinal pigment epithelium activity. Normal subjects].

Authors:  S Madachi-Yamamoto; D Yonemura; K Kawasaki
Journal:  Nippon Ganka Gakkai Zasshi       Date:  1984-10

6.  [Electrophysiological evaluation of retinal pigment epithelium for clinical use. (II) Hyperosmolarity response in normal subjects (author's transl)].

Authors:  S Madachi-Yamamoto
Journal:  Nippon Ganka Gakkai Zasshi       Date:  1982

7.  Hyperosmolarity response of ocular standing potential as a clinical test for retinal pigment epithelium activity. Normative data.

Authors:  S Madachi-Yamamoto; D Yonemura; K Kawasaki
Journal:  Doc Ophthalmol       Date:  1984-05-30       Impact factor: 2.379

8.  Clinicopathologic correlation of xenon arc and argon laser photocoagulation. Procedure in human diabetic eyes.

Authors:  I H Wallow; M D Davis
Journal:  Arch Ophthalmol       Date:  1979-12

9.  [Changed retinal cell content in diabetics (author's transl)].

Authors:  U Fuchs; A Reichenbach; H Siwula; G Taubert; P Winiecki
Journal:  Albrecht Von Graefes Arch Klin Exp Ophthalmol       Date:  1981

10.  Clinicopathologic study of blood-retinal barrier in experimental diabetes mellitus.

Authors:  M O Tso; J G Cunha-Vaz; C Y Shih; C W Jones
Journal:  Arch Ophthalmol       Date:  1980-11
View more
  3 in total

1.  Suppression of the hyperosmolarity response after cataract surgery.

Authors:  K Kawasaki; D Yonemura; T Yanagida; Y Segawa; K Wakabayashi; S Mukoh; H Ishida; S Fujii; Y Takahara
Journal:  Doc Ophthalmol       Date:  1986-11-15       Impact factor: 2.379

2.  Combined photic and nonphotic electro-oculographic responses in the clinical evaluation of the retinal pigment epithelium.

Authors:  T Mori; M F Marmor; K Miyoshi; Y Tazawa
Journal:  Doc Ophthalmol       Date:  1991       Impact factor: 2.379

Review 3.  Intake of dietary salt and drinking water: Implications for the development of age-related macular degeneration.

Authors:  Andreas Bringmann; Margrit Hollborn; Leon Kohen; Peter Wiedemann
Journal:  Mol Vis       Date:  2016-12-22       Impact factor: 2.367

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.